More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

Completed · Phase 1/Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this study was to determine the dosage for oral cabotegravir (CAB) and long-acting cabotegravir (CAB LA) and long-acting rilpiverine (RPV LA) and evaluate the safety, acceptability, tolerability, and pharmacokinetics (PK) of oral CAB, CAB LA, and RPV LA in virologically suppressed children and adolescents living with HIV.

Key facts

Study ID
NCT03497676
Run by
National Institute of Allergy and Infectious Diseases (NIAID)
People needed
168
Starts
2019-04-03
Expected to finish
2025-04-22
Last updated by the study team
2026-01-28

Who can join

Age: 12 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.